Bristol-Myers Dodges Revival Of Abilify FCA Suit At 6th Circ.
A Sixth Circuit panel on Friday declined to revive whistleblowers' False Claims Act suit against pharmaceutical companies Bristol-Myers and Otsuka over alleged kickbacks and off-label promotion for the antipsychotic drug Abilify,...To view the full article, register now.
Already a subscriber? Click here to view full article